Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.62
OMER's Cash to Debt is ranked higher than
60% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. OMER: 1.62 )
OMER' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 1.62

Equity to Asset 0.09
OMER's Equity to Asset is ranked higher than
50% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OMER: 0.09 )
OMER' s 10-Year Equity to Asset Range
Min: -15.24   Max: 0.7
Current: 0.09

-15.24
0.7
F-Score: 3
Z-Score: -3.22
M-Score: -6.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3157.25
OMER's Operating margin (%) is ranked higher than
53% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. OMER: -3157.25 )
OMER' s 10-Year Operating margin (%) Range
Min: -3157.25   Max: -605.88
Current: -3157.25

-3157.25
-605.88
Net-margin (%) -2487.25
OMER's Net-margin (%) is ranked higher than
53% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. OMER: -2487.25 )
OMER' s 10-Year Net-margin (%) Range
Min: -2487.25   Max: -630.99
Current: -2487.25

-2487.25
-630.99
ROA (%) -240.68
OMER's ROA (%) is ranked lower than
51% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. OMER: -240.68 )
OMER' s 10-Year ROA (%) Range
Min: -240.68   Max: -33.98
Current: -240.68

-240.68
-33.98
ROC (Joel Greenblatt) (%) -5379.77
OMER's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. OMER: -5379.77 )
OMER' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5379.77   Max: -1856.1
Current: -5379.77

-5379.77
-1856.1
Revenue Growth (%) -15.70
OMER's Revenue Growth (%) is ranked higher than
66% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. OMER: -15.70 )
OMER' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 7.7
Current: -15.7

0
7.7
EBITDA Growth (%) 0.80
OMER's EBITDA Growth (%) is ranked higher than
81% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. OMER: 0.80 )
OMER' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 0.8
Current: 0.8

0
0.8
EPS Growth (%) 0.50
OMER's EPS Growth (%) is ranked higher than
83% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. OMER: 0.50 )
OMER' s 10-Year EPS Growth (%) Range
Min: 0   Max: 0.5
Current: 0.5

0
0.5
» OMER's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

OMER Guru Trades in Q2 2013

Jim Simons 82,281 sh (-9.62%)
» More
Q3 2013

OMER Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2013

OMER Guru Trades in Q4 2013

Paul Tudor Jones 10,807 sh (New)
» More
Q1 2014

OMER Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OMER

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 82.30
OMER's P/B is ranked higher than
54% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. OMER: 82.30 )
OMER' s 10-Year P/B Range
Min: 2.76   Max: 82.4
Current: 82.3

2.76
82.4
P/S 713.20
OMER's P/S is ranked higher than
56% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. OMER: 713.20 )
OMER' s 10-Year P/S Range
Min: 0   Max: 713.2
Current: 713.2

0
713.2
EV-to-EBIT -7.85
OMER's EV-to-EBIT is ranked higher than
61% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OMER: -7.85 )
OMER' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -7.85

Current Ratio 5.29
OMER's Current Ratio is ranked higher than
78% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. OMER: 5.29 )
OMER' s 10-Year Current Ratio Range
Min: 0.41   Max: 6.61
Current: 5.29

0.41
6.61
Quick Ratio 5.29
OMER's Quick Ratio is ranked higher than
79% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. OMER: 5.29 )
OMER' s 10-Year Quick Ratio Range
Min: 0.41   Max: 6.61
Current: 5.29

0.41
6.61

Valuation & Return

vs
industry
vs
history
Price/Net Cash 349.80
OMER's Price/Net Cash is ranked higher than
70% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. OMER: 349.80 )
OMER' s 10-Year Price/Net Cash Range
Min: 3.62   Max: 301.75
Current: 349.8

3.62
301.75
Price/Net Current Asset Value 233.20
OMER's Price/Net Current Asset Value is ranked higher than
69% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. OMER: 233.20 )
OMER' s 10-Year Price/Net Current Asset Value Range
Min: 3.6   Max: 201.17
Current: 233.2

3.6
201.17
Price/Tangible Book 82.30
OMER's Price/Tangible Book is ranked higher than
58% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. OMER: 82.30 )
OMER' s 10-Year Price/Tangible Book Range
Min: 3.46   Max: 71
Current: 82.3

3.46
71
Price/Median PS Value 6.50
OMER's Price/Median PS Value is ranked lower than
51% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. OMER: 6.50 )
OMER' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 5.28
Current: 6.5

0.52
5.28
Forward Rate of Return (Yacktman) -40.40
OMER's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. OMER: -40.40 )
OMER' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -156.4   Max: -21.2
Current: -40.4

-156.4
-21.2

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:3O8.Germany
Omeros Corporation is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system. It derives product candidates from its proprietary PharmacoSurgery platform that is designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The Company's product candidates comprise OMS302, which is in Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program evaluating the product candidates safety and ability to improve postoperative joint function and reduce pain following arthroscopic partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. It also engages in developing proprietary compositions that comprise peroxisome proliferator-activated receptor gamma agonists for the treatment and prevention of addiction to substances of abuse. The Company's pipeline of preclinical product development programs includes PDE10 for schizophrenia/cognitive disorders; PDE7 for addictions and compulsive disorders, and movement disorders; MASP2 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; and Plasmin for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors programs for multiple disorders.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide